SCHEMBL7215918

SCHEMBL7215918

Oc1nc(SCCc2ccccc2)nc(-c2ccncc2)c1-c1ccc(F)cc1

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 14/20 0.49
MAPK13 O15264 1/20 0.48
GCGR P47871 1/20 0.48
MAPK12 P53778 1/20 0.48
MAPK11 Q15759 1/20 0.48
MAPK10 P53779 1/20 0.43
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2D6 P10635 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
HIF1A Q16665 1/20 0.41
SRC P12931 1/20 0.40
BRAF P15056 1/20 0.40
KDR P35968 1/20 0.40
CYP11B1 P15538 2/20 0.40
CYP11B2 P19099 2/20 0.40
KDM4E B2RXH2 1/20 0.40
ALDH1A1 P00352 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7211714 0.95 MAPK14 (0.52) MAPK14MAPK13GCGRMAPK12MAPK11
SCHEMBL7211830 0.86 MAPK14 (0.40) MAPK14MAPK13GCGRMAPK12MAPK11
SCHEMBL7216599 0.85 MAPK14 (0.47) MAPK14MAPK13GCGRMAPK12MAPK11
SCHEMBL7215276 0.77 MAPK14 (0.52) MAPK14MAPK13GCGRMAPK12MAPK11
SCHEMBL6934568 0.76 MAPK14 (0.62) MAPK14MAPK13GCGRMAPK12MAPK11
SCHEMBL27522556 0.75 MAPK14 (0.64) MAPK14MAPK13GCGRMAPK12MAPK11
SCHEMBL7216217 0.75 MAPK14 (0.50) MAPK14MAPK13GCGRMAPK12MAPK11
SCHEMBL4464755 0.72 MAPK14 (0.80) MAPK14MAPK13GCGRMAPK12MAPK11
SCHEMBL6934204 0.71 MAPK14 (0.59) MAPK14MAPK13GCGRMAPK12MAPK11
SCHEMBL6932122 0.70 MAPK14 (0.61) MAPK14MAPK13GCGRMAPK12MAPK11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1314731-A2 Substituted pyrimidine compounds and their use AMGEN INC. (US) 2003-05-28 EP claimed
US-20030069425-A1 Substituted pyrimidine compounds and methods of use AMGEN INC. 2003-04-10 US claimed
US-6410729-B1 ANALGESICS; ANTIDIABETIC AGENTS; ANTIINFLAMMATORY AGENTS AMGEN INC. 2002-06-25 US claimed
EP-1314732-A2 Substituted pyrimidine compounds and their use AMGEN INC. (US) 2003-05-28 EP disclosed
EP-1314731-A2 Substituted pyrimidine compounds and their use AMGEN INC. (US) 2003-05-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030069425-A1 Substituted pyrimidine compounds and methods of use DPYD, IL6, IL1B MAPK14 2062/4885MAPK13 2250/4885GCGR 2080/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.